K. Sanders

发表

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

M. Parmar, M. Sydes, D. Dearnaley, 2009, Trials.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2012, Trials.

A Trial of a Shorter Regimen for Rifampin‐Resistant Tuberculosis

A. Van Deun, K. Sanders, S. Meredith, 2019, The New England journal of medicine.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Bingshu E. Chen, M. Parmar, M. Sydes, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon-γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol

R. Horne, P. Whiting, A. Crook, 2021, BMJ Open.

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

M. Parmar, M. Sydes, D. Dearnaley, 2009, The Lancet. Oncology.

Flexible trial design in practice: Dropping and adding arms in STAMPEDE (MRC PR08, CRUK/06/019)-A multiarm, multistage randomized controlled trial.

M. Parmar, M. Sydes, D. Dearnaley, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis

J. Madan, A. Van Deun, K. Sanders, 2022, Trials.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

M. Parmar, M. Sydes, R. Cowan, 2011, The Lancet.

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi‐arm, multistage randomized controlled trial

John Dwyer, M. Sydes, D. Dearnaley, 2009, BJU international.

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

M. Parmar, M. Sydes, D. Dearnaley, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2012, The Lancet. Oncology.

Reflections on attempted Anglo–Japanese collaboration on STAMPEDE: A randomized controlled trial for men with prostate cancer

M. Sydes, N. James, N. Clarke, 2011, International journal of urology : official journal of the Japanese Urological Association.

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial

M. Parmar, M. Sydes, D. Dearnaley, 2011, Trials.

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy

N. Beeching, M. Johnson, K. Sanders, 2016, AIDS.

Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised contro

R. Horne, A. Crook, K. Sanders, 2022, BMJ Open.

Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110).

Bingshu E. Chen, M. Parmar, M. Sydes, 2012 .

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

L. Rigouts, K. Sanders, M. Gurumurthy, 2022, The Lancet.